TECH OUTLOOK 6MARCH - 2022TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comIn the modern world, traditional methods of cancer treatments like chemotherapy and radiation often fall short of delivering adequate relief. Nowadays, people are seeking personalized cancer treatment options that provide a higher chance of recovery. Additionally, immunotherapy experts are leaving no stone unturned in transforming the existing models, from autonomous treatment procedures to devising out-of-the-box solutions based on the latest technologies. Evidently, the cancer immunotherapy market is projected to register a CAGR of 9.8% during the forecast period, with a revenue of approximately USD 85,567 million in 2020 and expectedly USD 1,50,433 million by 2026. To that end, many new-age technology trends are being introduced in the immune-oncology therapeutic space. Technologies like predictive analysis and machine learning are playing a vital role in emphasizing patient-specific reasons for ailments and eventually generating a database of health symptoms for specific medical markers. Moreover, IoT and big data algorithms are paving the way for new routes in immunotherapy procedures. The current trends of nanotechnology in immunotherapy will boost the market growth. The nano-particles, which have dimensions of less than 100 nanometers, have been engineered to treat cancer. The benefits provided are active or passive attack of drugs, high solubility bioavailability, and multifunctionality. At the brink of immunotherapy technologies, there is a wide range of solutions providers offering the latest from a breed of next-generation pharmaceutical needs. To help leaders navigate the list of top immunotherapy solutions providers, our panel comprising industry analysts and the editorial board of Pharma Tech Outlook has narrowed down on some of the most prominent companies offering breakthrough immunotherapy technologies. Besides, the magazine also offers thought leadership from subject matter experts exclusive insights from CXOs. We hope this edition will provide you with the right assistance in choosing the best immunotherapy companies suited for your needs. Let us know your thoughts!Transforming Immunotherapy via TechnologyCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.MARCH - 7 - 2022, Vol 08 - Issue 01 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, TECH OUTLOOK
< Page 5 | Page 7 >